Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13107758 | 0.92 | GPR119 (0.74) | GPR119CYP2C9 | |
| SCHEMBL1893321 | 0.89 | GPR119 (0.57) | GPR119CYP2C9 | |
| SCHEMBL12236456 | 0.87 | GPR119 (0.69) | GPR119CYP2C9 | |
| SCHEMBL12259511 | 0.87 | GPR119 (0.69) | GPR119CYP2C9 | |
| SCHEMBL20375463 | 0.87 | GPR119 (0.71) | GPR119CYP2C9 | |
| SCHEMBL288503 | 0.86 | GPR119 (0.57) | GPR119CYP2C9 | |
| SCHEMBL12258475 | 0.86 | GPR119 (0.65) | GPR119CYP2C9 | |
| SCHEMBL12258980 | 0.86 | GPR119 (0.68) | GPR119CYP2C9 | |
| SCHEMBL1891474 | 0.85 | GPR119 (0.57) | GPR119CYP2C9 | |
| SCHEMBL20375633 | 0.85 | GPR119 (0.67) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382204-B1 | PYRIMIDINE DERIVATIVES AS GPCR MODULATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | MERCK SHARP & DOHME (US) | 2018-07-11 | — | — | EP | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722882-B2 | Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes | MERCK SHARP & DOHME CORP. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8546429-B2 | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8481731-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| EP-1644357-B1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1838697-A1 | PROCESSES FOR PREPARING 4-(PHENOXY-5-METHYL-PYRIMIDIN-4-YLOXY)PIPERIDINE-1-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS | Arena Pharmaceuticals, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007035355-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006076243-A1 | PROCESSES FOR PREPARING 4-(PHENOXY-5-METHYL-PYRIMIDIN-4-YLOXY)PIPERIDINE-1-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155129-A1 | Processes for preparing aromatic ethers | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| EP-1644357-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005007647-A9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005007647-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155129-A1 | Processes for preparing aromatic ethers | FABP4, GPR119, CYP2E1 | GPR119 2/4885CYP2C9 66/4885 |
| US-20130072427-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CYP2C9 1406/4885 |
| US-20070155763-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the phophylaxis and treatment of disorders related thereto | CYP27A1, CYP11B2, CYP11B1 | GPR119 6/4885CYP2C9 53/4885 |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | GPR119 13/4885CYP2C9 56/4885 |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | GPR3, GPR119, GPR84 | GPR119 2/4885CYP2C9 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.